Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Read now
Peng Men, Chaoyun Li, Suodi Zhai & Shuli Qu. (2020) Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China . Current Medical Research and Opinion 36:2, pages 213-217.
Read now
Read now
Marc Evans, Liana K. Billings, Jonas Håkan-Bloch, Ulla Slothuus, Trine J. Abrahamsen, Andreas Andersen & Jeroen P. Jansen. (2018) An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. Journal of Medical Economics 21:4, pages 340-347.
Read now
Read now
Willy Marcos Valencia & Hermes Jose Florez. (2015) A new angle for glp-1 receptor agonist: the medical economics argument. Journal of Medical Economics 18:12, pages 1029-1031.
Read now
Read now
Articles from other publishers (6)
Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou & Shihchen Kuo. (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
David R. Owens, Louis Monnier & Anthony H. Barnett. (2017) Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes, Obesity and Metabolism 19:10, pages 1339-1352.
Crossref
Crossref
Gabriela Vega-Hernandez, Radek Wojcik & Max Schlueter. (2017) Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy 8:3, pages 513-530.
Crossref
Crossref